An Open-label Phase 1b Study Of Pf-04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Higher-risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, Or Chronic Myelomonocytic Leukemia

Trial Profile

An Open-label Phase 1b Study Of Pf-04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Higher-risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, Or Chronic Myelomonocytic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Azacitidine (Primary) ; Glasdegib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BRIGHT 1012
  • Sponsors Pfizer
  • Most Recent Events

    • 29 May 2018 Planned number of patients changed from 170 to 72.
    • 17 May 2018 Planned number of patients changed from 72 to 170.
    • 17 May 2018 Planned End Date changed from 6 Nov 2021 to 1 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top